OUR MISSION

To Transform the Lives of  Cancer Patients with Unprecedented Targeted Precision.

Pioneering a Transformational and Disruptive Technology by a Novel Pan-Cancer First-in-Class mAb

Revealing a Previously Overlooked  
Diagnostic & Therapeutic Opportunity

NomoCan’s  
Breakthrough Discovery

First-in-Class
Conformational
Antibody & ADC

At NomoCan, we are building a revolutionary oncology platform that integrates high-specificity diagnostics with first-in-class monoclonal antibody therapeutics, precisely engineered to target a core cancer-driving pathway across multiple tumor types.

Our approach is

Highly Selective and Specific Tumor Target
Target expression across various solid and liquid tumors, absent in normal tissue

Robust First-in-Class Therapeutics
Pioneering the first and only therapeutic antibody approach against this novel target

Pan-Cancer by Design
Enabling both detection & precision-targeted therapy for some the most aggressive cancers

A Compelling ADC Opportunity
Optimal tumor-specific target properties, combined with robust efficacy of naked mAb, provide strong rationale for NomoCan’s ADC.

World Leading Scientific and Clinical Experts
Backed by 14+ years of domain expertise, that revealed a previously overlooked opportunity.

This is not an incremental step forward - THIS IS A PARADIGM SHIFT

First-in-Class
Conformational Antibodies

Historically, numerous companies have attempted to develop inhibitors against the wild-type protein but have faced dose-limiting toxicities due to its ubiquitous expression. By contrast, NomoCan’s novel mAb exclusively identifies specific protein variants in cancer cells, unlocking superior efficacy with a significantly improved safety profile.

Non-Invasive Liquid Biopsy Detection

The tumor-restricted nature of our First-in-Class antibody provides a strong foundation for the development of highly selective diagnostic and prognostic assays leveraging non-invasive liquid biopsy, enabling early detection, patient stratification, and precision-guided treatment strategies.

First-in-Class
ADC

Building on this breakthrough, NomoCan has developed a First-in-Class targeted ADC for the treatment of some of the most aggressive cancers with unmet medical need, with Pancreatic Cancer as our lead indication.

Pancreatic Cancer is a Dire Diagnosis

3rd Cause of Cancer Death

It is currently the 3rd leading cause of cancer-related death in the United States after lung and colon.

13% Survive

The five year survival rate for pancreatic cancer remains at only 12.8%.

80% Metastasized

Diagnosed when it has already metastasized in 80% of cases, making treatment more challenging.

Harmful Chemo Cocktails

Currently treated with chemotherapy cocktails, which kill cancer, but also wreak havoc on healthy tissues.

To improve these terrible outcomes, there is an urgent need for early detection and biomarker-driven therapies.

Unparalleled Precision Oncology Approach

LIQUID BIOPSY + NMC-521 mAb

First-in-Class
NMC-521

Selective

Specific

Highly Efficacious

Safe

Powering Early Detection and Precision Guided Oncology

Liquid Biopsy Diagnostics

Trans_AdobeStock_518810651_Preview copy.png

Revolutionizing cancer detection and treatment through integrated liquid diagnostics and targeted therapeutics.

Precision-Guided Treatment

Patient Stratification

Fully integrated with NMC-521 therapy. Delivering personalized, targeted oncology care.

Identifies patients most likely to respond
to NMC-521 and optimizes treatment selection and improves clinical outcomes.

Pipeline

NomoCan's monoclonal antibodies are able to selectively identify and diagnose cancer in human tumors. With a high affinity for their target, these antibodies demonstrate potent anti-tumor efficiency against freshly excised patient tumors as well as rodent models, providing a groundbreaking opportunity to initiate first-in-human clinical trials.